Navigation Links
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
Date:10/17/2008

MONTREAL, Oct. 17 /PRNewswire-FirstCall/ -- Today, at the Canadian Diabetes Association Congress, physicians will get a first-time look at more detailed results from a phase 3b clinical study (LEAD(TM) 6) comparing the investigational new drug liraglutide to exenatide. The study showed that liraglutide, a human GLP-1 analog administered once daily was significantly more effective at improving blood glucose control (as measured by HbA1c) than exenatide, a GLP-1 mimetic administered twice daily.

"In this study, reduction in blood glucose was greater with liraglutide than with exenatide," said Lawrence Blonde, MD, Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes, and Metabolism at the Oxford Center in New Orleans. "Patients treated with once-daily liraglutide achieved better blood glucose control and also had less minor hypoglycemia than those treated with exenatide."

Fasting plasma glucose was also reduced significantly more with liraglutide compared to exenatide. Furthermore, liraglutide was also associated with higher HOMA-B values, an assessment of beta-cell function.

The 26-week study included 464 people with type 2 diabetes who were randomized to treatment with either liraglutide 1.8 mg once daily or exenatide 10 micrograms twice daily, both as an add-on to their existing treatment consisting of metformin and/or a sulphonylurea.

The overall rate of hypoglycemia in the study was low. Liraglutide patients experienced significantly less minor hypoglycemia compared to those on exenatide.

Nausea was the most common side effect for both treatments and was reported at a level of 25.5% in the liraglutide group and 28% in exenatide group (percent of all study participants reporting nausea at least once). However, in the liraglutide group, the percentage of patients reporting nausea in each week fell to 8% after 5 weeks, 4% after 10 weeks and 3% after 26 weeks. In the exenatide gr
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a life ... products for advanced microarray diagnostics, today announced it will ... at 2:00 pm ET.  During the ... brief review of SQI,s recent commercialization progress and then ... veteran recently appointed to the Board of Directors of ...
(Date:8/18/2014)... August 18, 2014 According ... Market Research "Life Science Reagents Market(Products- PCR Reagent ... Chromatography, In-Vitro Diagnostic Reagents and Others; End Users- ... Clinical Laboratories, and Forensic Laboratories)- Global Industry Analysis, ... 2019", the global life science reagents market was ...
(Date:8/18/2014)... 2014 Vier führende deutsche Augenzentren ... Studie auf, in der eine Intraokularlinse (IOL) ... Sehvermögen bei allen Entfernungen verbessern, so dass ... Lese- oder Gleitsichtbrille mehr benötigen. Die neue ... Accommodating Intraocular Lens (FluidVision akkomodative Intraokularlinse) ...
(Date:8/15/2014)... LAKE FOREST, Ill. , Aug. 15, 2014 /PRNewswire/ ... the world,s leading provider of injectable drugs and infusion ... the Morgan Stanley Global Healthcare Conference on Tuesday, Sept. ... The presentation is scheduled to begin at ...  It will be available to all interested parties through ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... BioLife Solutions, Inc.,(OTC Bulletin Board: BLFS), a ... storage and cryopreservation media products for cells,tissues, ... Rutgers University Cell and DNA,Repository (RUCDR), ... the Company,s CryoStor as the exclusive cryopreservation ...
... Doubles Manufacturing Capacity; Expands Global Reach with Vietnam ... Alpine Biomed Corporation, a global leader in ... doubled its manufacturing capacity and expanded its worldwide ... The company will produce and distribute medical devices ...
... Conference Call Scheduled for 5:00 p.m. ETORANGE COUNTY, Calif., ... BEC ) announced today it will host a conference ... ET to discuss the company,s first quarter 2009 results. ... http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO )The call may be accessed by ...
Cached Biology Technology:Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media 2Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media 3Alpine Biomed Opens New Manufacturing Facility to Support Demand for Specialty Diagnostic Devices 2Alpine Biomed Opens New Manufacturing Facility to Support Demand for Specialty Diagnostic Devices 3Beckman Coulter Announces First Quarter 2009 Earnings to be Released on Tuesday, April 28, 2009, After Market Closes 2
(Date:8/19/2014)... Ill. A new study of 9- and 10-year-olds ... more fibrous and compact white-matter tracts in the brain ... describes the bundles of axons that carry nerve signals ... matter is associated with faster and more efficient nerve ... the open-access journal Frontiers in Human Neuroscience. , ...
(Date:8/18/2014)... 2014 ,Trustonic TEE ... smart devices  Trustonic, the leading provider ... and Fingerprint Cards AB (FPC) today announced a ... secure biometric authentication on connected devices. ... (FPC1020, FPC1021 and FPC1150) and sensor driver software ...
(Date:8/18/2014)... a new satellite image of Antarctica, and the imagery ... insight into the effects of climate change. , Thanks ... MacDonald, Dettwiler and Associates Ltd. (MDA), the prime contractor ... Network (CCIN) at UWaterloo, the mosaic is free and ... , Using Synthetic Aperture Radar with multiple polarization ...
Breaking Biology News(10 mins):Physically fit kids have beefier brain white matter than their less-fit peers 2Physically fit kids have beefier brain white matter than their less-fit peers 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4Waterloo makes public most complete Antarctic map for climate research 2
... edible dormice ( Glis glis ) are busy caring for ... to replenish their fat stores to cope with the upcoming ... pleasant taste and dormice have long been viewed as a ... fatten them up for eating, which explains the "edible" part ...
... pioneering online biology video sites, iBioSeminars and iBioMagazine, have ... with even more to offer the biology community. Following ... provide videos by world-class biologists for free. ... broad audience, says iBiology Director Sarah Goodwin PhD, including ...
... 2013 A study performed at Children,s Hospital Los Angeles ... children with optic nerve hypoplasia (ONH). Their results are reported ... Ophthalmology and Strabismus ( AAPOS ). ONH, an ... appear either as an isolated abnormality or as part of ...
Cached Biology News:Fat and fit 22 online science video pioneers combine to form new iBiology.org 2No evidence to support stem cell therapy for pediatric optic nerve hypoplasia 2No evidence to support stem cell therapy for pediatric optic nerve hypoplasia 3
... Physical Form: buffered aqueous solution. ... terminal galactose from complex carbohydrates and glycoproteins. ... galactose under conditions where the pH must ... live cells. Unit Definition: ...
... for human cardiac troponin subunit T, a 31kDa ... for contraction of cardiac muscle. It reacts with ... cells. It also cross-reacts with human skeletal troponin ... Highly purified human cardiac troponin T ...
cystatin A (N-18)...
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Biology Products: